There are no items in your cart
Add More
Add More
| Item Details | Price | ||
|---|---|---|---|
🎓 Limited Scholarship: Save ₹61,000 on Fellowships
Claim Your Scholarship
Get personalised advice on eligibility, fellowships, fees and scholarships.
Fill out the form and our team will share the prospectus on WhatsApp.
Polycystic ovary syndrome (PCOS) is a common hormonal and metabolic condition affecting women of reproductive age. Patients may present with irregular periods, acne, excess facial hair, difficulty conceiving or concerns about weight gain. Others may have few obvious symptoms despite an increased risk of metabolic complications.
For clinicians, a practical PCOS management clinic guide for doctors should go beyond menstrual symptoms. It should integrate accurate diagnosis, assessment of insulin resistance and cardiometabolic risk, individualised treatment, fertility goals and long-term follow-up.
PCOS management often involves collaboration between general practitioners, gynaecologists, endocrinologists and nutrition professionals. The aim is to address the patient’s concerns while reducing avoidable investigations and unnecessary treatment.
PCOS is a clinical diagnosis that requires careful assessment because its symptoms overlap with other endocrine and reproductive conditions.
In adults, the Rotterdam framework generally requires at least two of the following three features, after excluding alternative causes:
When irregular cycles and hyperandrogenism are both present, ovarian ultrasound or AMH is not usually required to establish the diagnosis. AMH should not be used as a standalone test for PCOS. Diagnostic approaches in adolescents differ because normal pubertal changes can resemble PCOS.
Take a menstrual history, including cycle frequency, duration and the date of the last period. Ask about acne, unwanted hair growth, scalp hair thinning, fertility concerns, weight changes and relevant family history.
Examine the patient for signs of hyperandrogenism and metabolic risk. Rapid onset of severe androgen-related symptoms, deepening of the voice or other signs of virilisation require prompt investigation for alternative causes.
Before confirming PCOS, consider conditions such as thyroid dysfunction, hyperprolactinaemia and non-classic congenital adrenal hyperplasia. Additional testing depends on the presentation and may be needed when an androgen-secreting tumour or another endocrine disorder is suspected.
Avoid diagnosing PCOS based on an ultrasound report alone. Polycystic ovarian morphology can occur in people who do not have the syndrome.
PCOS is associated with an increased risk of impaired glucose regulation, type 2 diabetes, dyslipidaemia and other cardiometabolic problems. However, metabolic assessment should be based on clinical needs rather than assumptions about every patient.
Assess glycaemic status at diagnosis and repeat testing according to individual risk and clinical guidance. A 75-g oral glucose tolerance test (OGTT) is considered the most accurate assessment of glycaemic status in PCOS, regardless of BMI. Fasting glucose and HbA1c may be alternatives when an OGTT is not feasible, although they may be less sensitive in some patients.
Repeat assessment based on risk factors, previous results and changes in clinical status. Pregnancy planning is an important opportunity to review glucose regulation.
Obtain a lipid profile at diagnosis and assess blood pressure regularly. Interpret cholesterol and triglyceride results alongside other cardiovascular risk factors, family history and the patient’s overall health.
Weight, waist circumference and BMI can provide useful context, but they should be discussed sensitively. PCOS can occur at different body sizes, and a normal BMI does not eliminate metabolic risk.
Insulin resistance is an important part of PCOS biology, but routine insulin measurements are generally not recommended for diagnosing or managing PCOS because available assays and clinical thresholds have limitations.
Instead, evaluate clinically relevant outcomes such as glucose regulation, blood pressure and lipid levels. Investigate further when symptoms or findings indicate another endocrine or metabolic condition.
Lifestyle intervention is a foundation of PCOS care. Treatment should be tailored to the patient’s symptoms, preferences, metabolic health and reproductive goals.
Encourage regular physical activity, including aerobic exercise and resistance training where appropriate. A balanced eating pattern with vegetables, pulses, whole grains, suitable protein sources and minimally processed foods can support metabolic health.
No single diet is universally superior for PCOS. Recommendations should be practical, culturally appropriate and sustainable rather than based on restrictive diets or promises of a quick hormonal cure.
Discuss sleep, stress, emotional wellbeing and barriers to maintaining lifestyle changes. Screen for disordered eating and consider psychological support when needed.
Metformin may be considered for metabolic outcomes, particularly in adults with PCOS who have a BMI of 25 kg/m² or above, while individual circumstances and local guidance remain important. It can improve some metabolic measures and may support menstrual regularity in selected patients, but it is not the best option for every symptom.
Discuss gastrointestinal side effects and gradual dose adjustment where appropriate. Long-term use may be associated with vitamin B12 deficiency, so consider monitoring in patients with relevant risk factors or symptoms.
Metformin should not be presented as a guaranteed weight-loss treatment or as a universal fertility medicine. The choice depends on the patient’s primary treatment goal.
GLP-1 receptor agonists may be considered for weight management in eligible patients with PCOS when they meet the applicable criteria for obesity treatment. Evidence suggests that some patients may experience weight reduction and improvements in certain metabolic outcomes, but the evidence base for PCOS-specific outcomes continues to develop.
These medicines are not a universal first-line treatment for PCOS and should not be prescribed solely because a patient has the diagnosis. Review approved indications, contraindications, adverse effects, cost and the likelihood of long-term treatment.
Discuss pregnancy plans before treatment. GLP-1-based medicines are not intended for weight loss during pregnancy, and product-specific guidance on stopping treatment before conception must be followed. Weight regain may occur after discontinuation, making ongoing lifestyle support important.
Treatment depends on whether the patient is seeking pregnancy, wants predictable menstrual cycles or primarily needs help with androgen-related symptoms.
Patients with infrequent periods may need treatment to reduce prolonged exposure of the endometrium to unopposed oestrogen. Depending on the clinical circumstances, options may include combined oral contraceptives or periodic progestogen therapy.
Combined oral contraceptives may also help manage irregular cycles and symptoms of hyperandrogenism when appropriate. Assess contraindications, including relevant thromboembolic and cardiovascular risks, before prescribing.
Patients should be advised to seek review if they experience prolonged amenorrhoea or unexpected heavy bleeding.
For patients seeking pregnancy, discuss preconception health, glucose assessment, blood pressure, weight-related concerns and medication safety.
Letrozole is generally recommended as the first-line pharmacological ovulation-induction treatment for anovulatory infertility due to PCOS when no other infertility factors are present. Treatment requires appropriate clinical assessment and monitoring.
Patients with additional infertility factors or unsuccessful initial treatment may need specialist fertility evaluation. Metformin alone should not automatically replace evidence-based ovulation-induction treatment.
PCOS is associated with an increased likelihood of type 2 diabetes and other metabolic risk factors. Patients may also experience anxiety, depression, body-image concerns and reduced quality of life.
A long-term plan should include periodic review of glucose status, blood pressure, lipids, menstrual patterns and treatment response. The frequency of testing should reflect the patient’s individual risk rather than a fixed schedule for everyone.
Ask about mood, sleep and the emotional impact of symptoms. Unwanted hair growth, acne, fertility difficulties and weight stigma can affect wellbeing even when laboratory results appear reassuring.
Clear explanations can help patients understand that PCOS is manageable and that treatment goals may change over time. Avoid suggesting that weight loss is the only meaningful measure of improvement.
In adults, diagnosis generally requires two of three features: hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology or an appropriately elevated AMH result. Alternative causes must first be excluded.
There is no single treatment for every patient. Lifestyle support is foundational, while medication depends on whether the priority is menstrual regulation, androgen-related symptoms, metabolic health or fertility.
They may help eligible patients manage weight and some metabolic outcomes, but they are not a universal first-line PCOS treatment. Pregnancy planning, safety, approved indications and long-term management must be considered.
PCOS is associated with increased risk of impaired glucose regulation, type 2 diabetes and other metabolic abnormalities. Menstrual dysfunction may also increase the risk of endometrial hyperplasia when prolonged amenorrhoea is not managed appropriately.
Effective PCOS management requires an individualised approach that combines accurate diagnosis, metabolic assessment, symptom control and reproductive planning. Doctors should avoid unnecessary tests, explain the limits of available treatments and monitor long-term health risks.
For clinicians seeking further education in women’s metabolic health, the Fellowship or Certificate in Gynaecology and Obstetrics, Endocrinology and Clinical Nutrition programmes offered by Virtued Academy International may be relevant learning options. Review the curriculum, eligibility and clinical training details before enrolling.
